Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$1.9B |
| 2 |
Boeing
BA
|
+$956M |
| 3 |
Netflix
NFLX
|
+$804M |
| 4 |
EOG Resources
EOG
|
+$761M |
| 5 |
Wells Fargo
WFC
|
+$721M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity National Information Services
FIS
|
+$1.3B |
| 2 |
Nike
NKE
|
+$1.17B |
| 3 |
AbbVie
ABBV
|
+$1.16B |
| 4 |
McDonald's
MCD
|
+$1.15B |
| 5 |
Texas Instruments
TXN
|
+$987M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.27% |
| 2 | Technology | 16.8% |
| 3 | Communication Services | 12.6% |
| 4 | Consumer Discretionary | 11.05% |
| 5 | Financials | 7.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Telus
TU
$15B
| $317M | 0.1% |
16,369,706
+6,038,816
| +58% | +$112M |
|
177
Sarepta Therapeutics
SRPT
$1.94B
| $311M | 0.09% |
+2,409,053
| New | +$243M |
|
178
Haemonetics
HAE
$4.16B
| $310M | 0.09% |
2,694,800
+143,800
| +6% | +$17.4M |
|
179
AT&T
T
$166B
| $309M | 0.09% |
10,461,038
+6,204
| +0.1% | +$179K |
|
180
Helen of Troy
HELE
$696M
| $300M | 0.09% |
1,667,557
+160,554
| +11% | +$25.8M |
|
181
Sherwin-Williams
SHW
$87.4B
| $297M | 0.09% |
1,528,602
+9
| +0% | +$1.72K |
|
|
LK
182
DELISTED
Luckin Coffee Inc. American Depositary Shares
LK
| $297M | 0.09% |
7,540,284
+210,800
| +3% | +$5.33M |
|
183
Zoetis
ZTS
$30.4B
| $289M | 0.09% |
+2,183,112
| New | +$271M |
|
|
PRAH
184
DELISTED
PRA Health Sciences, Inc.
PRAH
| $286M | 0.09% |
2,575,986
-176,803
| -6% | -$18.2M |
|
185
Thor Industries
THO
$4.11B
| $283M | 0.08% |
3,802,954
+2,272,954
| +149% | +$147M |
|
186
Oneok
OKE
$58.3B
| $282M | 0.08% |
3,728,998
+393,054
| +12% | +$28.1M |
|
|
RDS.A
187
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $281M | 0.08% |
4,767,512
+89,327
| +2% | +$5.22M |
|
188
Applied Materials
AMAT
$435B
| $278M | 0.08% |
4,554,943
-573,735
| -11% | -$32.2M |
|
189
Automatic Data Processing
ADP
$107B
| $276M | 0.08% |
1,618,806
+311,927
| +24% | +$51.6M |
|
190
Kimberly-Clark
KMB
$36.2B
| $276M | 0.08% |
2,005,570
+1,567
| +0.1% | +$212K |
|
191
MongoDB
MDB
$35.2B
| $275M | 0.08% |
2,092,275
+135,083
| +7% | +$17.7M |
|
192
Vertex Pharmaceuticals
VRTX
$133B
| $274M | 0.08% |
1,250,649
+379
| +0% | +$76.7K |
|
193
Frontdoor
FTDR
$5.89B
| $273M | 0.08% |
5,759,200
+25,000
| +0.4% | +$1.17M |
|
194
Ultragenyx Pharmaceutical
RARE
$2.65B
| $272M | 0.08% |
6,362,695
+5,514
| +0.1% | +$228K |
|
195
Wynn Resorts
WYNN
$10.6B
| $261M | 0.08% |
1,879,930
-399,492
| -18% | -$48.6M |
|
196
Visa
V
$671B
| $261M | 0.08% |
1,387,237
+1,456
| +0.1% | +$262K |
|
197
Valvoline
VVV
$4.25B
| $250M | 0.07% |
11,663,237
+171,011
| +1% | +$3.77M |
|
198
Cannae Holdings
CNNE
$651M
| $248M | 0.07% |
6,658,759
+38,759
| +0.6% | +$1.27M |
|
199
Gaming and Leisure Properties
GLPI
$12.5B
| $247M | 0.07% |
5,740,683
+292,233
| +5% | +$12M |
|
200
Danaher
DHR
$145B
| $244M | 0.07% |
1,794,105
+1,320
| +0.1% | +$167K |
|
Similar funds
Capital Research Global Investors's Q4 2019 Portfolio in Review
As of Q4 2019, Capital Research Global Investors held 433 positions worth $333B, up 9.4% from $305B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Capital Research Global Investors's Q4 2019 filing shows 19 new, 239 increased, 105 reduced and 28 closed positions. Its largest new stake was Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A: 415,754 shares worth $490M. The largest sale was Fidelity National Information Services, an estimated $1.3B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Communication Services.
- Capital Research Global Investors's largest Q4 2019 buy was Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A: 415,754 shares worth $490M.
- Capital Research Global Investors added most to UnitedHealth in Q4 2019, an estimated $1.9B increase.
- Capital Research Global Investors's biggest Q4 2019 reduction was Fidelity National Information Services, cutting an estimated $1.3B.
- Capital Research Global Investors fully exited 3M in Q4 2019, selling an estimated $654M.
- Capital Research Global Investors's ten largest holdings make up 30% of its $333B portfolio in Q4 2019.
- Capital Research Global Investors opened 19 new positions and closed 28 in Q4 2019.
- Capital Research Global Investors's portfolio value rose 9.4% quarter-over-quarter to $333B.
Based on Capital Research Global Investors's 13F filing for Q4 2019, filed 18 Feb 2020.